ArticleMarine biotechnology (New York, N.Y.)2026
Immunoinformatics-Based Design of a Multiple-Epitope Vaccine Against IHNV.
Article in Marine biotechnology (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Genomics-Guided Epitope Prioritization and in Silico Design of a Multi-Epitope DNA Vaccine Candidate Against Megalocytivirus pagrus 1.Marine biotechnology (New York, N.Y.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious hematopoietic necrosis virus (IHNV) is a significant viral pathogen that affects salmonids, leading to high mortality and substantial economic losses in aquaculture. The current vaccine strategies focus on use of DNA and inactivated vaccines. However, these strategies face limitations concerning biosafety and efficacy. Therefore, in this work, we employed an approach based on the immunoinformatic platform to develop a multi-epitope vaccine against IHNV. For that purpose, we analyzed the glycoprotein of IHNV and identified highly antigenic and non-allergenic cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and B-cell epitopes. The different epitopes were assembled with rational linkers, and the N-terminal flagellin FliC adjuvant was added to enhance immunogenicity. The designed vaccine showed favorable physicochemical properties and high structural stability, which was validated through modeling and refinement. Moreover, the molecular docking of the designed vaccine with toll-like receptor 5 (TLR5) and molecular dynamics simulation revealed stable and strong interactions between the vaccine and TLR5, demonstrating that the designed vaccine can activate innate immunity. Furthermore, in silico immune simulations demonstrate a robust humoral and cellular immune response following multiple doses. These findings provide a promising framework for the development of a novel, safe, and effective vaccine against the IHNV infection in Atlantic salmon.
Indexed as
Identifiers
42113364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.